**Abstract**

**Objective:** Chronic depression is common and associated with significant functional impairment (Haykal & Akiskal, 1999). Desvenlafaxine is effective in the treatment of major depression (Thase et al., 2009), yet there is no data on its efficacy in the treatment of persistent depressive disorder. The aim of this study was to investigate the efficacy, safety and tolerability of desvenlafaxine monotherapy in patients with persistent depressive disorder.

**Methods:** Thirty-five patients with persistent depressive disorder consented to participate in an open-label 8-week trial of monotherapy with desvenlafaxine. Primary efficacy measures were administered at baseline, weeks 1, 2, 4, and week 8.The dose of desvenlafaxine was fixed (50mg/day) until week 4, after which it was flexible up to 100mg/day, based on response and tolerability.

**Results:** Montgomery Asberg Depression Scale scores significantly decreased from baseline (*M*=23.61, *SD*=5.51) to end of treatment (*M*=12.29, *SD*=8.41), *p*\<.0001. Severity of illness, as measured by the Clinical Global Impression scale, as well as self-reported depressive symptom scores, significantly decreased from baseline to end of treatment (*p*\<.0001). Improvement in quality of life (p\<.0001), levels of perceived stress (p\<.0001), coping styles (p\<.0001), and work impairment (p\<.01) were noted over the course of treatment.

**Conclusions:** Overall results indicate that desvenlafaxine is effective in reducing depressive symptoms and improving functioning in patients with persistent depressive disorder. Further, results provide evidence of good safety and tolerability of desvenlafaxine in this population. These results support the further investigation of desvenlafaxine for this condition using larger, placebo controlled, randomized control trials.
